REVIVED-BCIS2预设分析:缺血性左室功能不全血运重建后心律失常与死亡
REVIVED-BCIS2试验预设分析纳入700例严重左室功能不全、广泛冠心病且有存活心肌患者,随机接受PCI+最佳药物和器械治疗或单纯药物治疗。结果显示两组全因死亡或中止性猝死无差异(41.6% vs 40.2%,HR 1.03,95%CI 0.82-1.30,P=0.80),PCI未降低致命性室性心律失常。
要点
- PCI未降低全因死亡或中止性猝死风险(HR 1.03,P=0.80)。
- 在缺血性心肌病患者中,仅为减少致命性室性心律失常而行PCI无获益。
- 预设分析支持优化药物和器械治疗为基础管理策略。
核心结论
- PCI与全因死亡或中止性猝死减少无关。
- 在缺血性心肌病患者中,仅为减少潜在致命性室性心律失常而行PCI无获益。
研究设计与样本
- 随机对照试验预设分析,纳入700例严重左室功能不全、广泛冠心病且有存活心肌患者,随机分为PCI+最佳药物和器械治疗组(347例)或单纯最佳药物和器械治疗组(353例)。
- 主要复合终点为至少24个月的全因死亡或中止性猝死(适当ICD治疗或复苏成功的心脏骤停),按意向性治疗分析至首次事件时间。
主要发现
- 全因死亡或中止性猝死发生在PCI组144例(41.6%)和单纯药物组142例(40.2%),风险比1.03(95%CI 0.82-1.30),P=0.80。
- 任何次要结局均无组间差异。
关键数值与推荐
- 平均年龄69岁;88%为男性;56%有高血压;41%有糖尿病;53%有心肌梗死临床病史。
- 左室射血分数中位数28%;53.1%在随机化前或随访期间植入ICD。
临床怎么用
- 对于缺血性心肌病患者,不应仅为减少致命性室性心律失常而常规行PCI。
- 优化药物和器械治疗仍是基础管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ventricular arrhythmia is an important cause of mortality in patients with ischemic left ventricular dysfunction. Revascularization with coronary artery bypass graft or percutaneous coronary intervention is often recommended for these patients before implantation of a cardiac defibrillator because it is assumed that this may reduce the incidence of fatal and potentially fatal ventricular arrhythmias, although this premise has not been evaluated in a randomized trial to date. METHODS: Patients with severe left ventricular dysfunction, extensive coronary disease, and viable myocardium were randomly assigned to receive either percutaneous coronary intervention (PCI) plus optimal medical and device therapy (OMT) or OMT alone. The composite primary outcome was all-cause death or aborted sudden death (defined as an appropriate implantable cardioverter defibrillator therapy or a resuscitated cardiac arrest) at a minimum of 24 months, analyzed as time to first event on an intention-to-treat basis. Secondary outcomes included cardiovascular death or aborted sudden death, appropriate implantable cardioverter defibrillator (ICD) therapy or sustained ventricular arrhythmia, and number of appropriate ICD therapies. RESULTS: Between August 28, 2013, and March 19, 2020, 700 patients were enrolled across 40 centers in the United Kingdom. A total of 347 patients were assigned to the PCI+OMT group and 353 to the OMT alone group. The mean age of participants was 69 years; 88% were male; 56% had hypertension; 41% had diabetes; and 53% had a clinical history of myocardial infarction. The median left ventricular ejection fraction was 28%; 53.1% had an implantable defibrillator inserted before randomization or during follow-up. All-cause death or aborted sudden death occurred in 144 patients (41.6%) in the PCI group and 142 patients (40.2%) in the OMT group (hazard ratio, 1.03 [95% CI, 0.82-1.30]; P=0.80). There was no between-group difference in the occurrence of any of the secondary outcomes. CONCLUSIONS: PCI was not associated with a reduction in all-cause mortality or aborted sudden death. In patients with ischemic cardiomyopathy, PCI is not beneficial solely for the purpose of reducing potentially fatal ventricular arrhythmias. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01920048.
引用
- Perera D, Morgan HP, Ryan M, et al. Arrhythmia and Death Following Percutaneous Revascularization in Ischemic Left Ventricular Dysfunction: Prespecified Analyses From the REVIVED-BCIS2 Trial. Circulation. 2023. PMID: 37555345. doi:10.1161/CIRCULATIONAHA.123.065300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。